Abacavir

Evidence Level: L5

Predicted Indications: 3

Abacavir

Pharmacist Assessment Report

Abacavir: Nucleoside reverse transcriptase inhibitor → feline acquired immunodeficiency syndrome

One-Sentence Summary

Abacavir is a nucleoside reverse transcriptase inhibitor (NRTI) used against HIV. The TxGNN model predicts it may be effective for feline acquired immunodeficiency syndrome, a veterinary condition, but the data compiled for this report contain 0 clinical trials and only 1 publication, an older in vitro study of a three-drug combination.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	feline acquired immunodeficiency syndrome
TxGNN Prediction Score	0.9979
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (9 of 9) – CDSCO approval status is not included in this data
Number of Listed Products	9 (valid: 9)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data are not available in the data compiled for this report. Based on general knowledge, abacavir belongs to the NRTI class, which blocks the reverse transcriptase enzyme that HIV uses to copy its genetic material.

Feline immunodeficiency virus (FIV) is a lentivirus whose reverse transcriptase is related to that of HIV. For this reason, it is biologically plausible that NRTIs could act against FIV. The single publication found (2002) tested a combination of zidovudine, lamivudine and abacavir against FIV in vitro. Abacavir’s own contribution cannot be separated from the combination.

This is a veterinary indication with no direct human clinical relevance. The study does not directly establish efficacy of abacavir for feline AIDS in animals, so the evidence level is capped at L5.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
11684314	2002	Preclinical combination study (inferred from title)	Antiviral Research	Zidovudine, lamivudine and abacavir combination therapy was evaluated for suppression of FIV replication in vitro. The cat is discussed as an animal model for HIV. Full text was not reviewed.

India Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
7370	A Bec L 600mg/300mg Tablet	Strip of 30 tablets	Not recorded
108303	Inbec Tablet	Bottle of 30 tablets	Not recorded
1957	Abamune Tablet	Strip of 30 tablets	Not recorded
236242	Virol 300mg Tablet	Bottle of 60 tablets	Not recorded
2296	Abamune L 600 mg/300 mg Tablet	Strip of 30 tablets	Not recorded

Safety Considerations

Drug Interactions: 93 interactions were recorded. The ones listed with a Moderate level are naltrexone and orlistat. The others shown have an unclassified level, including metformin, omeprazole, pantoprazole, lansoprazole, morphine, prednisone, hydrocortisone, vancomycin, amphotericin B and sulfasalazine.
Other information: Abacavir is known to carry a risk of HLA-B*5701-associated hypersensitivity. Package insert warnings and contraindications were not available in the data compiled for this report, so please refer to the package insert for full safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests on a model score and one in vitro combination study from 2002 that cannot isolate abacavir’s effect. The indication is also veterinary, so it has no direct human therapeutic relevance.

To proceed, the following is needed:

Studies that test abacavir alone against FIV, with in vivo data in cats
Confirmation of whether a veterinary development path is relevant to this programme
Mechanism of action data and package insert warnings and contraindications
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.